Insider trade report
Open the filing on sec.gov
DexCom, Inc. (DXCM)
Nasdaq: DXCM · Surgical & Medical Instruments & Apparatus · San Diego, CA · filing with the SEC since 2002
Grade6.5
◀ Past 7.2● Present 6.7▶ Future 5.6
The companyfiscal 2025, as filed
Revenue$4.66B+15.6%
Net income$836M+45.1%
Earnings per share$2.09+47.2%
Operating cash flow$1.44B+45.6%
Cash$918M+51.4%
Debtn/a
Shareholders’ equity$2.75B+30.6%
Shares, diluted405.5M-1.7%
Return on equity30.5%
The recordfrom its filings
Filings in 2026116
Newest filingNov 10 · 4
Annual reportFeb 12, 2026
Quarterly reportOct 29, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$12.8M
Insider buys, 12 months$0.00
Patents granted972
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $5.10BNet income $991MCash from operations $1.41Bthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.